These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 26753208)

  • 1. [Prediction of response to TNF-α inhibitors treatment with use of swollen to tender joint count ratio (STR)].
    Kardas T; Majdan M; Gągoł D; Mazurek M
    Wiad Lek; 2015; 68(3):248-51. PubMed ID: 26753208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is swollen to tender joint count ratio a new and useful clinical marker for biologic drug response in rheumatoid arthritis? Results from a Swedish cohort.
    Kristensen LE; Bliddal H; Christensen R; Karlsson JA; Gülfe A; Saxne T; Geborek P
    Arthritis Care Res (Hoboken); 2014 Feb; 66(2):173-9. PubMed ID: 23982986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Joint involvement in patients affected by systemic lupus erythematosus: application of the swollen to tender joint count ratio.
    Cipriano E; Ceccarelli F; Massaro L; Spinelli FR; Alessandri C; Perricone C; Valesini G; Conti F
    Reumatismo; 2015 Sep; 67(2):62-7. PubMed ID: 26492964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: do we need to revise our assessment criteria?
    El Miedany Y; Youssef SS; El Gaafary M
    J Rheumatol; 2006 Mar; 33(3):490-7. PubMed ID: 16511918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Look beyond the disease activity score of 28 joints (DAS28): tender points influence the DAS28 in patients with rheumatoid arthritis.
    Ton E; Bakker MF; Verstappen SM; Ter Borg EJ; van Albada-Kuipers IA; Schenk Y; van der Veen MJ; Bijlsma JW; Jacobs JW;
    J Rheumatol; 2012 Jan; 39(1):22-7. PubMed ID: 22002014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study.
    Gomez-Reino JJ; Maneiro JR; Ruiz J; Roselló R; Sanmarti R; Romero AB;
    Ann Rheum Dis; 2012 Nov; 71(11):1861-4. PubMed ID: 22736086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patients with active rheumatoid arthritis but only few tender and swollen joints: a subgroup with impaired short term outcome.
    Fiehn C; Kessler S; Drexler W; Lorenz HM
    Rheumatol Int; 2009 Apr; 29(6):655-61. PubMed ID: 18998141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study.
    Bartelds GM; Wijbrandts CA; Nurmohamed MT; Stapel S; Lems WF; Aarden L; Dijkmans BA; Tak PP; Wolbink GJ
    Ann Rheum Dis; 2010 May; 69(5):817-21. PubMed ID: 19581278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longterm retention of tumor necrosis factor-α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors.
    Iannone F; Gremese E; Atzeni F; Biasi D; Botsios C; Cipriani P; Ferri C; Foschi V; Galeazzi M; Gerli R; Giardina A; Marchesoni A; Salaffi F; Ziglioli T; Lapadula G;
    J Rheumatol; 2012 Jun; 39(6):1179-84. PubMed ID: 22467933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is pre-assessment for anti-TNF therapy in RA necessary in the UK? Analysis of DAS28 in six centres.
    Smith N; Gadsby K; Butt S; Carruthers D; Deeming A; Ledingham J; Fletcher M; Mulherin D; Roskell S; Kay L; Nicholl K; Cooper R; Worsley A; Deighton C
    Rheumatology (Oxford); 2007 Oct; 46(10):1557-9. PubMed ID: 17666440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Remission in rheumatoid arthritis by different criteria does not converge over the inflammatory markers.
    Chandrashekara S; Priyanka BU
    Int J Rheum Dis; 2013 Jun; 16(3):291-6. PubMed ID: 23981750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of a third tumor necrosis factor-α-blocking agent compared with rituximab after failure of 2 TNF-blocking agents in rheumatoid arthritis.
    Blom M; Kievit W; Donders AR; den Broeder AA; Straten VH; Kuper I; Visser H; Jansen TL; Brus HL; Branten AJ; van de Laar MA; van Riel PL
    J Rheumatol; 2011 Nov; 38(11):2355-61. PubMed ID: 21885487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
    Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
    Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab.
    Zikou AK; Argyropoulou MI; Voulgari PV; Xydis VG; Nikas SN; Efremidis SC; Drosos AA
    J Rheumatol; 2006 Feb; 33(2):219-23. PubMed ID: 16465650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study.
    Burmester GR; Ferraccioli G; Flipo RM; Monteagudo-Sáez I; Unnebrink K; Kary S; Kupper H
    Arthritis Rheum; 2008 Jan; 59(1):32-41. PubMed ID: 18163417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Knee joint destruction driven by residual local symptoms after anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Imagama T; Tanaka H; Tokushige A; Seki K; Sumiura S; Yamamoto M; Nagahiro Y; Taguchi T
    Clin Rheumatol; 2013 Jun; 32(6):823-8. PubMed ID: 23377200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of methotrexate effect on the acute-phase response in rheumatoid arthritis after 12-week treatment].
    Murav'ev IuV; Gridneva GI; Karateev DE; Luchikhina EL; Omonin IuL; Aleksandrova EN; Kashnikova LN; Glukhova SI; Nasonov EL
    Klin Med (Mosk); 2014; 92(3):59-63. PubMed ID: 25269199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating to a target in established active rheumatoid arthritis patients receiving a tumor necrosis factor inhibitor: results from a real-world cluster-randomized adalimumab trial.
    Pope JE; Haraoui B; Rampakakis E; Psaradellis E; Thorne C; Sampalis JS;
    Arthritis Care Res (Hoboken); 2013 Sep; 65(9):1401-9. PubMed ID: 23509040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML; Christensen IJ; Tarp U; Dreyer L; Hansen A; Hansen IT; Kollerup G; Linde L; Lindegaard HM; Poulsen UE; Schlemmer A; Jensen DV; Jensen S; Hostenkamp G; Østergaard M;
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.